There are 2789 resources available
1506MO - Incorporating genetic and non-genetic risk factors in breast cancer risk prediction for healthy women with non-informative genetic test result
Presenter: Anja Tüchler
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
1507MO - Selection of quality indicators (QI) by non-hospital professionals for onco-hematology care pathway
Presenter: Mario di Palma
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
228MO - PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
Presenter: Binghe Xu
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
229MO - Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
Presenter: Miguel Martin Jimenez
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1510MO_PR - European cancer patients’ perspectives on Immunotherapy
Presenter: Paraskevas Kosmidis
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
659MO - Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)
Presenter: Nieves Martinez Chanza
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA31 - High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2)
Presenter: Jeroen Van Dorp
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1508MO - Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)
Presenter: Lucia Notario Rincon
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
1509MO - Adherence to the Food and Drug Administration (FDA) guidance for the co-development of two or more investigational new drugs in phase 1/2 cancer trials
Presenter: Justin Moyers
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
230MO - First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies
Presenter: Matthew Krebs
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast